Additional Details
-
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
GSK Investigational SitePhiladelphia PA. 19140 -
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
GSK Investigational SiteNaples FL. 34102 -
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
MGH Institute of Health ProfessionsCharlestown MA. 02129 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
UCLA Health Westwood Medical PlazaWestwood CA. 90095 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Washington University (Site #: 71191)Saint Louis MO. 63130 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
University of Pennsylvania (Site #: 71111)Philadelphia PA. 19104 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Cincinnati Children's Hospital Medical Center (Site #: 71017)Cincinnati OH. 45229 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
University of California, Los Angeles (Site #: 71123)Los Angeles CA. 90095 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Cleveland Clinic (Site #: 71101)Cleveland OH. 44195 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
University Health Network/Toronto General Hospital (Site #: 71121)Toronto ON. M5G 2N2 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Johns Hopkins (Site #: 71119)Baltimore MD. 21287 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Duke University (Site #: 71139)Durham NC. 27710 -
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
MD Anderson Cancer CenterHouston TX. 77030 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteMontréal QC. H2X 0A9 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteEdmonton AB. T6G 2C8 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteSherbrooke QC. J1H 5N4 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteVancouver BC. V6Z 2K5 -
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
University of California San FranciscoSan Francisco CA. 94143 -
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
University of MichiganAnn Arbor MI. 48109